drugset / Trial / NCT07815522
Abiraterone With Dalpiciclib in Salivary Gland Carcinoma
Phase 2
Recruiting
36 enrolled
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NaSingle-groupOpen-labelTreatment
Summary
This study is a single center, non controlled, prospective phase II clinical trial to evaluate the efficacy and safety of abiraterone combined with dalpiciclib in recurrent/metastatic salivary gland carcinoma patients with AR positive and Her-2 negative. The participants would receive abiraterone combined with dalpiciclib until termination criteria are met.
Timeline
- Start
- 2026-10-01
- Primary completion
- 2028-10-01
- Completion
- 2029-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1 g | Oral |
| Subject | Dalpiciclib | Small molecule | 150 mg | — |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |